The price monopoly of Active Pharmaceutical Ingredient has been severely hit, with three pharmaceutical companies penalized and a total of 0.325 billion. Tianjin Tianyao Pharmaceuticals has been involved in four cases over four years | Brief announcement.

① Due to the establishment and implementation of a monopoly agreement on sodium dexamethasone active pharmaceutical ingredients, Tianjin Tianyao Pharmaceuticals, Jiangsu Lianhuan Pharmaceutical, and Zhejiang Xianju Pharmaceutical were collectively fined 0.325 billion yuan; ② The fines will impact the performance of each company, with the fines for Tianjin Tianyao Pharmaceuticals and Jiangsu Lianhuan Pharmaceutical accounting for 51.85% and 72.53% of their net income from last year respectively; ③ Tianjin Tianyao Pharmaceuticals has been fined four times in four years for violating the Anti-Monopoly Law, with total fines exceeding 0.17 billion yuan.

cls.cnApr 30 19:13 ET

After "7 days and 5 boards", Qianjiang Yongan Pharmaceutical refutes the rumors of "taurine price skyrocketing" | Quick reading of the announcement.

① Qianjiang Yongan Pharmaceutical has again reached its price limit today, with a Turnover Ratio of 31%, recording 5 price limits within 7 days; ② The company stated that the rumors circulating online recently about "taurine prices skyrocketing several times" are false; ③ After turning a profit in 2024, Qianjiang Yongan Pharmaceutical fell back into loss again in the first quarter of this year.

cls.cnApr 29 11:01 ET

Nanjing King-Friend Biochemical Pharmaceutical turned a profit last year, but its net profit in Q1 this year halved year-on-year | Interpretations

① After clearing the inventory risk of heparin Active Pharmaceutical Ingredient, Nanjing King-Friend Biochemical Pharmaceutical successfully turned losses into profits last year; ② The impact of centralized procurement mainly reduced the gross margin of key products, with pressure continuing into this year, and the first quarter's Net income nearly halved; ③ Tariffs from the USA have not yet had a significant impact on the company's Business, but the company will focus on developing markets outside the USA.

cls.cnApr 28 12:00 ET

Jiangsu Hengrui Pharmaceuticals: Authorized revenue becomes the "accelerator" for performance.

Personnel, products, and research and development are gradually becoming Global.

wallstreetcnApr 24 07:29 ET

The upfront payment for the new ADC drug has boosted revenue, Jiangsu Hengrui Pharmaceuticals' Q1 revenue increased by 20.14% year-on-year, and net income increased by 36.9% | Earnings Reports insights.

In Q1, Jiangsu Hengrui Pharmaceuticals' revenue increased by 20.14% year-on-year, net income attributable to the parent company increased by 36.9%, and net income after deductions increased by 29.35% year-on-year. The significant increase in net income was primarily due to the company receiving a $75 million upfront payment for external licensing.

wallstreetcnApr 24 06:03 ET

Fumetinib drives performance growth, Shanghai Allist Pharmaceuticals Co., Ltd. expects net profit to increase by over 120% year-on-year in 2024.

① During the reporting period, Shanghai Allist Pharmaceuticals Co., Ltd. achieved revenue of 3.558 billion yuan, a year-on-year increase of 76.29%; net income attributable to shareholders was 1.43 billion yuan, up 121.97% year-on-year, and net income excluding extraordinary items was 1.361 billion yuan, an increase of 124.51% year-on-year; ② The net cash flow reached 1.566 billion yuan, a growth of 132.12% compared to 0.675 billion yuan in the same period last year. Ample funds are beneficial for expanding R&D investment.

cls.cnApr 24 00:28 ET